Identifies a tumor suppressor that is mutated in a wide range of cancers, causing loss of expression in a number of human tumors, including breast, prostate, and endometrial cancer, and may be observed in Cowden syndrome tumors. Loss of PTEN expression may be a prognostic and predictive biomarker in breast and prostate cancer, correlating positively with advanced stage disease. Recent studies have reported that PTEN may be a powerful predictor of response to Herceptin in HER2 positive breast cancer.
A formalin-fixed, paraffin-embedded (FFPE) tissue block is preferred specimen typeorOne (1) unbaked, unstained slide for H&E staining (required) and two to three (2-3) positively charged unstained slides (all cut at 4-5 microns) for each test/antibody orderedBlock and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.